212,421 Shares in STAAR Surgical Company $STAA Acquired by Versor Investments LP

Versor Investments LP purchased a new stake in shares of STAAR Surgical Company (NASDAQ:STAA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 212,421 shares of the medical instruments supplier’s stock, valued at approximately $5,708,000. STAAR Surgical makes up about 1.1% of Versor Investments LP’s investment portfolio, making the stock its 13th largest position. Versor Investments LP owned 0.43% of STAAR Surgical as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Broadwood Capital Inc. increased its stake in shares of STAAR Surgical by 8.5% in the second quarter. Broadwood Capital Inc. now owns 13,519,491 shares of the medical instruments supplier’s stock valued at $226,857,000 after buying an additional 1,064,227 shares in the last quarter. Yunqi Capital Ltd grew its holdings in STAAR Surgical by 24.4% during the 2nd quarter. Yunqi Capital Ltd now owns 2,411,288 shares of the medical instruments supplier’s stock worth $40,461,000 after acquiring an additional 473,699 shares during the last quarter. Soleus Capital Management L.P. grew its holdings in STAAR Surgical by 16.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier’s stock worth $50,084,000 after acquiring an additional 421,840 shares during the last quarter. Federated Hermes Inc. acquired a new stake in STAAR Surgical in the 2nd quarter valued at about $6,095,000. Finally, Resona Asset Management Co. Ltd. raised its stake in shares of STAAR Surgical by 11.6% in the second quarter. Resona Asset Management Co. Ltd. now owns 2,421,836 shares of the medical instruments supplier’s stock worth $40,746,000 after acquiring an additional 252,218 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

Shares of STAA stock opened at $17.41 on Tuesday. The firm’s 50 day moving average price is $22.14 and its two-hundred day moving average price is $24.81. STAAR Surgical Company has a 52-week low of $13.50 and a 52-week high of $30.81. The stock has a market cap of $865.97 million, a PE ratio of -8.93 and a beta of 1.06.

Analysts Set New Price Targets

STAA has been the topic of several research analyst reports. Stifel Nicolaus decreased their price target on shares of STAAR Surgical from $28.00 to $19.00 and set a “hold” rating on the stock in a research note on Monday. Jefferies Financial Group dropped their price objective on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating for the company in a research report on Wednesday, January 28th. BTIG Research reiterated a “neutral” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 6th. Finally, Wells Fargo & Company boosted their target price on STAAR Surgical from $28.00 to $30.75 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, STAAR Surgical presently has an average rating of “Reduce” and a consensus price target of $20.36.

Insider Buying and Selling

In related news, major shareholder Broadwood Partners, L.P. bought 27,485 shares of the business’s stock in a transaction on Friday, January 9th. The shares were purchased at an average price of $22.05 per share, with a total value of $606,044.25. Following the completion of the purchase, the insider owned 15,453,629 shares of the company’s stock, valued at $340,752,519.45. This represents a 0.18% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders bought a total of 1,934,138 shares of company stock valued at $50,485,791 in the last ninety days. Corporate insiders own 0.59% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.